PurposeEpidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors have proven
efficacy in advanced non-small-cell lung cancer (NSCLC). We hypothesized that erlotinib …

Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …

Introduction Currently, limited data on tyrosine kinase inhibitors as neoadjuvant therapy
exist. This prospective study aimed to investigate the efficacy and safety of preoperative …

Background Although neoadjuvant chemotherapy could improve survival outcome in
resectable non–small cell lung cancer (NSCLC), the efficacy of neoadjuvant targeted …

Background Adjuvant chemotherapy remains the most important treatment for stage IIIA non-
small cell lung cancer (NSCLC) after radical operation, but its benefits has reached plateau …

Background: Adjuvant platinum-based chemotherapy is standard of care for patients with
resected stage IIA/B or IIIA NSCLC. Overall survival is suboptimal due to the high metastatic …

Purpose The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase
inhibitor (TKI) targeted therapy for patients with EGFR-mutant non-small cell lung cancer …

A 67-year-old never-smoking woman, who had been treated for four malignancies in the last
30 years (sarcoma of a lower extremity, bilateral breast cancer, and several basal cell …

As expected, more promising were the results of three completed studies (all performed in
China), enrolling selected patients with EGFR-mutant tumors. The first of them, a small …

Background Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung
cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant …